Department of Health and Human Services
National Institutes of Health
Toggle navigation
Search
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
How to Search
Contact Us
Search the Studies
Go Back
Searched Result
109 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number
Title
Protocol Status
Min-Max Age
Institute
Keywords
001730-C
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination with Immunotherapy Vaccine PRGN-2009 in Subjects with Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Participants currently recruited/enrolled
18-120 Years
NCI
Squamous Carcinoma
001564-C
A Phase II Sequential Window of Opportunity Trial of Pembrolizumab + N-803 alone or in Combination with PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Recruitment has not started
18-120 Years
NCI
Squamous Carcinoma
001545-C
A Phase Ib/II Multicenter Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
Recruitment has not started
18-120 Years
NCI
Squamous Carcinoma
001536-C
Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 with Pembrolizumab before Standard Treatment in Subjects with Newly Diagnosed HPV-Associated Oropharyngeal Cancer
Participants currently recruited/enrolled
18-120 Years
NCI
Squamous Carcinoma
001535-C
A Phase II Study of Sacituzumab Govitecan with or without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer
Recruitment has not started
18-120 Years
NCI
Squamous Carcinoma
001533-C
A Phase II Multicenter Study of Enfortumab Vedotin with or without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
Recruitment has not started
18-120 Years
NCI
Squamous Carcinoma
001109-C
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Participants currently recruited/enrolled
8-125 Years
NCI
Squamous Carcinoma
000462-C
Phase 2, Open-label, Single-arm, Window of Opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients With Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Squamous Carcinoma
21-DC-0002
Phase II Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss among Individuals with Head and Neck Cancer
Participants currently recruited/enrolled
18-100 Years
NIDCD
Squamous Carcinoma
20-C-0024
A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-beta trap (M7824 ) Alone and in Combination with TriAd Vaccine, and N-803 for Resectable Head and Neck Squamous Cell Carcinoma not Associated with Human Papillomavirus Infection.
Completed Study; data analyses ongoing
18-120 Years
NCI
Squamous Carcinoma
19-C-0041
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Completed Study; data analyses ongoing
18-125 Years
NCI
Squamous Carcinoma
19-C-0016
Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors
Participants currently recruited/enrolled
0-125 Years
NCI
Squamous Carcinoma
16-C-0154
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers
Participants currently recruited/enrolled
18-120 Years
NCI
Squamous Carcinoma
14-C-0104
A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived from Patients with Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen
Participants currently recruited/enrolled
18-72 Years
NCI
Squamous Carcinoma
001886-C
A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
Participants currently recruited/enrolled
18-120 Years
NCI
Carcinoma
001837-C
A Phase I Study to Establish the Feasibility of Enolen(TM) for the Local Delivery of Enzalutamide in Patients with Prostate Cancer
Participants currently recruited/enrolled
21-120 Years
NCI
Carcinoma
001733-C
A Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma
Participants currently recruited/enrolled
18-100 Years
NCI
Carcinoma
001731-C
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Recruitment has not started
18-120 Years
NCI
Carcinoma
001601-C
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Recruitment has not started
18-120 Years
NCI
Carcinoma
001587-C
A Phase I Dose-escalation Study of Preoperative Radiation Therapy in Participants with Resectable Recurrent Abdominal Adrenocortical Carcinoma
Recruitment has not started
18-120 Years
NCI
Carcinoma
001578-C
A Phase 1/2 Study of Tiragolumab (NSC# 827799, IND# 161266) and Atezolizumab (NSC# 783608, IND# 161266) in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Participants currently recruited/enrolled
3-100 Years
NCI
Carcinoma
001572-C
A Phase II Study of Bevacizumab in Adults with Recurrent Respiratory Papillomatosis (RRP)
Participants currently recruited/enrolled
18-120 Years
NCI
Squamous
001559-C
A Feasibility Multicenter Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Recruitment has not started
18-120 Years
NCI
Carcinoma
001557-C
Phase I/II Trial of Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination with HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants with Advanced or Metastatic Endometrial Cancer (EC)
Participants currently recruited/enrolled
18-120 Years
NCI
Carcinoma
001552-C
Phase II Study of Enasidenib in IDH2-mutated Malignant Sinonasal and Skull Base Tumors
Participants currently recruited/enrolled
18-120 Years
NCI
Carcinoma
001548-C
A Phase I/II Study of CDX-1140, a CD40 Agonist, in Combination with Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects with Biliary Tract Carcinoma (BTC)
Participants currently recruited/enrolled
0-120 Years
NCI
Carcinoma
001547-C
A First-in-Human Phase I Trial with Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
Participants currently recruited/enrolled
18-120 Years
NCI
Carcinoma
001523-C
A Phase II Study of Lurbinectedin with or without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Participants currently recruited/enrolled
18-120 Years
NCI
Carcinoma
001099-C
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-Fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
001004-C
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon Oncosignature(R) Status
Participants currently recruited/enrolled
18-120 Years
NCI
Carcinoma
000954-C
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients with Advanced Mesothelin-Expressing Cancer
No longer recruiting/follow-up only
18-120 Years
NCI
Carcinoma
000930-C
A Phase 1b/2 Study of HCW9218, a Bifunctional TGF-beta Antagonist/IL-15 Protein Complex, for Advanced Pancreatic Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000666-C
A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Participants currently recruited/enrolled
18-100 Years
NCI
Carcinoma
000596-C
Phase II Study of Olaparib in Subjects with Advanced Pancreatic Acinar Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000580-C
A Phase 1/2, Open Label Dose-Escalation and Expansion Trial of Nkt2152, an Orally Administered Hif2(alpha) Inhibitor, to Investigate Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinom
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000520-C
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG with or without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Clinical hold/Recruitment or enrollment suspended
18-125 Years
NCI
Carcinoma
000491-C
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000473-C
A Randomized Phase II Study of Systemic Chemotherapy with or without HAI FUDR-Dexamethasone in Patients with Unresectable Intrahepatic Cholangiocarcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000354-C
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000317-C
A Phase II, Open-Label Trial of PT-112 in Subjects with Thymoma and Thymic Carcinoma
Participants currently recruited/enrolled
18-120 Years
NCI
Carcinoma
000302-C
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000254-C
A Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000237-C
Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis from Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000080-C
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
000045-C
A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and other KK-LC-1 Positive Epithelial Cancers
Participants currently recruited/enrolled
18-120 Years
NCI
Carcinoma
22-C-0005
Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
22-C-0004
A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer
Participants currently recruited/enrolled
12-120 Years
NCI
Carcinoma
21-C-0030
Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
21-C-0023
A Phase I Study of Pomalidomide and Nivolumab in Patients with Virus-Associated Malignancies with or without HIV
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
21-C-0012
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis from Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
21-C-0007
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
Participants currently recruited/enrolled
18-120 Years
NCI
Squamous
20-CC-0039
A Feasibility Study to Evaluate the Combination of Electromagnetic Tracking and Optical Imaging with Indocyanine Green (ICG) for Hepatic Biopsies
Enrolling by Invitation
18-100 Years
CC
Carcinoma
20-C-0155
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination with BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) with CV301 TRICOM in Advanced Solid Tumors (STAT)
Completed Study; data analyses ongoing
18-120 Years
NCI
Squamous
20-C-0149
Phase II Trial of Olaparib (LYNPARZA) plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas that Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
20-C-0142
A Phase II Study of Bintrafusp alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects with Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
20-C-0097
A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects with Thymoma and Thymic Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
20-C-0051
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
Enrolling by Invitation
18-120 Years
NCI
Squamous
20-C-0045
Phase I/II Trial of Combination Immunotherapy in Subjects with Advanced HPV Associated Malignancies
No longer recruiting/follow-up only
18-125 Years
NCI
Squamous
20-C-0022
Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC)
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
20-C-0013
Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
20-C-0012
A Phase I Study of Bintrafusp alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Metastatic Non-Prostate Genitourinary Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
20-C-0009
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung Cancer
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
20-C-0006
A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-C-0137
A Phase II Study of Ipilimumab, Cabozantinib, and NIvolumab in Rare Genitourinary Cancers (ICONIC)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-C-0129
A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy with Oral Capecitabine for Gastric Adenocarcinoma with Peritoneal Carcinomatosis
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
19-C-0094
A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC)
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
19-C-0039
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
19-C-0033
Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic Cancers
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
19-C-0023
A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and other genitourinary tumors with DNA-Repair Defects
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
18-H-0012
A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients with Metastatic Clear Cell Renal Cell Carcinoma
No longer recruiting/follow-up only
18-75 Years
NHLBI
Carcinoma
18-DK-0091
Long-Term Follow-Up Of Subjects With CHC Who Achieved A Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
No longer recruiting/follow-up only
18-120 Years
NIDDK
Carcinoma
18-C-0147
Phase 1 with Expansion Cohorts in a Study of NEO-201 In Adults with Chemo-Resistant Solid Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
18-C-0138
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma.
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
18-C-0110
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers
Participants currently recruited/enrolled
18-99 Years
NCI
Carcinoma
18-C-0062
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Completed Study; data analyses ongoing
2-30 Years
NCI
Carcinoma
18-C-0024
A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy with Floxuridine and Dexamethasone in Combination with Systemic Chemotherapy for Patients with Colorectal Cancer Metastatic to the Liver
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
18-C-0008
Phase III Randomized Adjuvant study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) versus Observation
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
17-C-0157
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (oportuzumab monatox, VB4-845) in Subjects with High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated with Bacillus Calmette-Gu(SqrRoot)(Copyright)rin (BCG)
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
17-C-0140
Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural Mesotheliomas
Completed Study; data analyses ongoing
18-99 Years
NCI
Carcinoma
17-C-0092
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
17-C-0086
An Open-label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
17-C-0066
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma after Progression on Platinum-Based Chemotherapy
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
17-C-0011
Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron(R) (Peginterferon alfa-2b) and Actimmune(R) (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
16-C-0135
A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
16-C-0128
A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
16-C-0121
A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
16-C-0107
A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
Carcinoma
15-D-0129
Open-Label, Dose-Escalation Study Evaluating the Safety of a Single Administration of an Adeno-Associated Virus Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in Individuals with Irradiation-Induced Parotid Salivary Hypofunction.
No longer recruiting/follow-up only
18-100 Years
NIDCR
Squamous
15-C-0160
A Phase I Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
15-C-0157
Phase I/II Trial of Vandetanib in Combination with Metformin in Subjects with HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
15-C-0150
A Phase I/II Trial of Topotecan with VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
15-C-0099
A Phase 1, Open-Label, Dose-Escalation Study of SNX-5422 and Everolimus in Subjects with Neuroendocrine Tumors
Completed Study; data analyses ongoing
18-100 Years
NCI
Carcinoma
15-AR-0144
Studies of Dermatologic Diseases-Biospecimen Acquisition Protocol
Participants currently recruited/enrolled
0-100 Years
NIAMS
Carcinoma
14-C-0037
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
13-C-0118
A Phase I/II Trial of TRC102 (methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas
Completed Study; data analyses ongoing
18-120 Years
NCI
Carcinoma
12-C-0205
A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
12-C-0178
Longitudinal Assessment and Natural History Study of Children and Adults with MEN2A or MEN2B with or without Medullary Thyroid Carcinoma
Participants currently recruited/enrolled
0-125 Years
NCI
Carcinoma
12-C-0118
A Phase II Study of Sunitinib in Patients with Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma with at Least One Prior Line of Platinum-Based Systemic Chemotherapy
No longer recruiting/follow-up only
18-100 Years
NCI
Carcinoma
11-CC-0152
The Natural History of Liver Disease in a Cohort of Participants with Hepatitis B and/or Hepatitis C with or without HIV Infection
Completed Study; data analyses ongoing
18-99 Years
CC
Carcinoma
11-C-0140
A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
11-C-0096
Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
No longer recruiting/follow-up only
18-125 Years
NCI
Carcinoma
10-C-0166
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab
Participants currently recruited/enrolled
18-72 Years
NCI
Carcinoma
10-C-0114
A Phase II Study of Bevacizumab and Erlotinib in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
09-C-0161
Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
Enrolling by Invitation
18-125 Years
NCI
Carcinoma
08-H-0186
Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity with Bortezomib
Completed Study; data analyses ongoing
18-70 Years
NHLBI
Carcinoma
07-C-0121
Phase 2 Study of the C-Met RTK Inhibitor Foretinib (Formerly GSK 1363089) in Subjects with Papillary Renal Cell Carcinoma (PRC)
Completed Study; data analyses ongoing
18-125 Years
NCI
Carcinoma
05-CC-0091
Electromagnetic Tracking of Devices During Interventional Procedures
Enrolling by Invitation
18-120 Years
CC
Carcinoma
02-C-0064
Collection of Peripheral Blood and/or Urine From Patients Undergoing Radiation Therapy
Enrolling by Invitation
18-125 Years
NCI
Carcinoma
89-C-0086
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
Participants currently recruited/enrolled
2-125 Years
NCI
Carcinoma